Ossur hf represents a strong commitment to innovation and excellence in the orthopedic industry. With a mission to improve people's lives through high-quality prosthetic and orthotic products, Ossur focuses on creating innovative solutions that enhance mobility and independence for individuals with limb loss or musculoskeletal conditions. The company values include a customer-centric approach, integrity, teamwork, and a drive for continuous improvement. Ossur's corporate philosophy is centered around embracing diversity, fostering a culture of collaboration, and consistently delivering superior products and services to meet the ever-evolving needs of its global customer base.

Ossur hf is primarily present in several countries and regions worldwide. It has a significant presence in North America, with operations in the United States and Canada. Moreover, Ossur hf maintains a strong foothold in Europe, particularly in countries such as Germany, France, the United Kingdom, and the Nordic countries. Additionally, Ossur hf has expanded its reach to emerging markets, including China and India, where it has established a notable presence. By operating in these diverse regions, Ossur hf demonstrates its commitment to providing its innovative orthopedic solutions globally.

Ossur hf has achieved several significant milestones over the years. One major accomplishment was the development and commercialization of the Rheo Knee, a groundbreaking prosthetic knee that improved mobility for amputees. The company also introduced the innovative Proprio Foot, utilizing advanced sensor technology to provide a more natural walking experience. Ossur hf's commitment to research and development has led to the development of industry-leading products such as the Unity Vacuum System and the Re-Flex Rotate Ankle. These milestones have solidified Ossur hf's reputation as a global leader in orthopedic solutions and have greatly benefited individuals living with limb loss.

Ossur hf is an Icelandic company with a rich history and background. Established in 1999, Ossur specializes in the development, manufacturing, and marketing of non-invasive orthopedic products. With a focus on prosthetics, bracing, and supports, Ossur has become a global leader in advanced healthcare solutions. The company's success is attributed to its dedication to innovation, quality, and customer satisfaction. Ossur's products have positively impacted the lives of millions, helping individuals regain mobility, independence, and an active lifestyle. As a socially responsible company, Ossur continues to invest in research and development, ensuring the best possible solutions for orthopedic patients worldwide.

The main competitors of Ossur hf in the market include companies like Stryker Corporation, Zimmer Biomet Holdings, Inc., and Össur hf. These companies compete with Ossur hf in the orthopedic and prosthetic industry, offering similar products and solutions. However, Ossur hf, as a leading global provider of orthopedic products, has established a strong market presence and differentiates itself through innovative technologies, superior product quality, and a wide range of offerings.

Ossur hf is primarily active in the healthcare industry, specializing in orthopedic solutions.

The business model of Ossur hf is focused on designing, manufacturing, and selling non-invasive orthopedic solutions. Ossur specializes in creating innovative prosthetic and orthotic products that enhance the mobility and quality of life for individuals with physical disabilities. The company operates globally, serving both healthcare professionals and end-users. Ossur's business model revolves around continuous research and development, utilizing advanced technology and collaboration with healthcare providers to deliver cutting-edge solutions. With a strong emphasis on customer satisfaction and improved outcomes, Ossur remains dedicated to improving the lives of people with limb loss or mobility challenges.

P/E odnos Embla Medical hf iznosi 21,08.

KUV kompanije Embla Medical hf iznosi 2,06.

AlleAktien kvalitativni skor za Embla Medical hf je 6/10.

očekivana Embla Medical hf promet je 968,97 mil. USD.

Dobit očekivana Embla Medical hf je 94,70 mil. USD.

Ossur hf is an internationally active company specializing in the development, manufacturing, and distribution of medical products and solutions. The company was founded in Iceland in 1971 and has since become a global leader in orthopedic technology. The business model of Ossur is focused on developing innovative and high-quality products and services that improve the lives of people with physical disabilities and injuries. The company is divided into several business areas, each targeting different products and target groups. The prosthetics division offers a wide range of artificial limbs tailored to the individual needs and requirements of each user. The products range from simple, affordable prosthetics to high-tech systems that can record and control the wearer's movements using state-of-the-art technology and sensors. In the orthotics division, Ossur develops and produces a variety of orthotics that help heal joint and muscle injuries and improve the well-being of patients. The products range from simple knee and foot orthotics to complex hip orthotics and back braces. Another business area of Ossur is the supply of walking aids such as canes, crutches, and walkers. These products are commonly used by elderly people and patients with mobility problems and are characterized by high functionality and user-friendliness. In addition to the mentioned business areas, Ossur also offers a range of solutions and services tailored to the specific requirements of doctors, physiotherapists, and other medical professionals. These include training programs, further education, and technical support. The company conducts research and development at the highest level to stay up to date with the latest technology and develop innovative products. Ossur collaborates closely with medical institutions, universities, and research institutes to incorporate the latest scientific findings into their own products. Ossur aims to help patients with physical disabilities and injuries lead active and fulfilling lives. The company places great emphasis on quality, reliability, and innovation and strives to ensure that people worldwide have access to the best medical products and solutions. Overall, Ossur's business model is focused on meeting the needs and requirements of patients and medical professionals to the best possible extent while guaranteeing the highest standards of quality, safety, and user-friendliness. The company has a wide range of products, a strong research and development department, and an international network of distribution partners, enabling it to successfully operate in global markets.

Embla Medical hf isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Embla Medical hf trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Embla Medical hf je IS0000000040.

WKN od Embla Medical hf je 755122.

Oznaka za praćenje akcija kompanije Embla Medical hf je EMBLA.CO.

U poslednjih 12 meseci, Embla Medical hf je isplatio dividendu u iznosu od 0,15 USD . To odgovara dividendnom prinosu od oko 3,16 %. Za narednih 12 meseci, Embla Medical hf će verovatno isplatiti dividendu od 1,49 USD.

Dividendski prinos od Embla Medical hf trenutno iznosi 3,16 %.

Embla Medical hf isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima април, април, април, април.

Embla Medical hf je isplaćivao dividendu svake godine u poslednjih 6 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 1,49 USD. To odgovara dividendnom prinosu od 31,33 %.

Embla Medical hf se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Embla Medical hf od 26. 3. 2020. u iznosu od 0,15 USD, morali ste da imate akciju u depou pre Ex-dana 13. 3. 2020..

Isplata poslednje dividende izvršena je 26. 3. 2020..

U godini 2024 kompanija Embla Medical hf je isplatila 0 USD kao dividende.

Dividende od Embla Medical hf se isplaćuju u USD.